Vitti Labs Announces FDA Approval of Phase II IND Clinical Trial of Combination Mesenchymal Stem Cell and Exosome Treatment of Pulmonary Fibrosis Secondary to Novel Corona Virus Infection (COVID-19)

Vitti Labs announced that the FDA approved their Investigational New Drug Application to move forward with Phase II Outpatient Clinical Trial using a combination of umbilical cord MSCs and MSC Exosomes for the treatment of pulmonary fibrosis secondary to COVID-19.
[Vitti Labs (Yahoo! Finance)]
Press Release

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News